Immunology

Limited economic evidence for vitiligo treatments

(HealthDay)—The cost burden associated with vitiligo is high, although no evidence exists for the value of vitiligo treatments, according to a research letter published online Aug. 10 in the British Journal of Dermatology.

Diseases, Conditions, Syndromes

Risk for vitiligo increased for transplant recipients

Transplant recipients, especially those receiving hematopoietic stem cell transplant (HSCT), have an increased risk for vitiligo, according to a brief report published online Dec. 13 in JAMA Dermatology.

page 4 from 4